Xanthohumol and Viral Infections (XL)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Xanthohumol, Placebo.
- Who it may be relevant to
- Registry conditions: Infection Viral. Basic parameters: 18 years — 70 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Austria
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Xanthohumol in the Prevention of Virus-mediated Upper Respiratory Tract Infections in Humans
Overview
The aim of the present study is to determine if a regular oral supplementation of xanthohumol attenuate the severity of symptoms and duration of´viral infections.
Detailed description
In this placebo-controlled study, blood is taken on the first day of the study, followed by a 90-day intervention with xanthohumol or a placebo, which is taken twice daily. Blood samples will be taken on day 0, day 45 and day 90. Should the study participants develop a respiratory infection during the study, they will be asked to perform a self-test.
Interventions
- Dietary supplement Xanthohumol
Participants consume twice per day a study drink which contains 0,75 mg soluble Xanthohumol for 90 days - Dietary supplement Placebo
Participants consume twice per day a study drink which contains 0 mg soluble Xanthohumol for 90 days
Primary outcome measures
- Changes in severity and duration of viral infections [Time frame: 90 days]
Secondary outcome measures (2)
- Changes in blood lipid levels [Time frame: 90 days]
- Changes in cognitive skills [Time frame: 90 days]
Eligibility criteria
Inclusion criteria
- healthy
- BMI >18 kg/m² or < 28kg/m²
Exclusion criteria
- food intolerances
- food allergies
- chronic inflammatory diseases
- metabolic diseases
- viral or bacterial infections within the last 3 weeks of inclusion
- intake of immunosuppressive medication
- severe acute respiratory syndrome coronavirus type 2-infection in the last 4 months
- influenza infection in the "current" flu season
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Basic science
Study locations
Austria · 1 center
- University of Vienna — Vienna
Identifiers
NCT: NCT06286657 · UVienna23a